Cantor Fitzgerald Comments on MIRM FY2025 Earnings

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Mirum Pharmaceuticals in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will earn ($1.55) per share for the year. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.45) per share.

A number of other brokerages have also commented on MIRM. Citigroup raised their price target on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Leerink Partners boosted their price target on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. HC Wainwright reiterated a “buy” rating and issued a $66.00 price objective on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Finally, Robert W. Baird raised their price objective on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $57.10.

Mirum Pharmaceuticals Stock Up 4.1 %

MIRM opened at $48.65 on Thursday. The stock’s 50 day moving average price is $43.65 and its 200 day moving average price is $41.40. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. The stock has a market cap of $2.34 billion, a P/E ratio of -24.08 and a beta of 0.98. Mirum Pharmaceuticals has a 12 month low of $23.14 and a 12 month high of $49.27.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.15. The company had revenue of $90.38 million for the quarter, compared to analyst estimates of $81.99 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. Mirum Pharmaceuticals’s revenue was up 89.4% compared to the same quarter last year. During the same quarter last year, the business earned ($0.57) earnings per share.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of MIRM. R Squared Ltd purchased a new stake in Mirum Pharmaceuticals in the 4th quarter worth about $69,000. Secure Asset Management LLC lifted its position in Mirum Pharmaceuticals by 9.3% in the 4th quarter. Secure Asset Management LLC now owns 39,920 shares of the company’s stock worth $1,651,000 after buying an additional 3,406 shares in the last quarter. Avanza Fonder AB acquired a new stake in shares of Mirum Pharmaceuticals during the 4th quarter valued at $189,000. Hennion & Walsh Asset Management Inc. grew its holdings in shares of Mirum Pharmaceuticals by 25.5% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 145,599 shares of the company’s stock valued at $6,021,000 after acquiring an additional 29,545 shares in the last quarter. Finally, Lord Abbett & CO. LLC acquired a new position in shares of Mirum Pharmaceuticals in the third quarter worth $28,913,000.

Insider Transactions at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 750 shares of the company’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total transaction of $32,115.00. Following the completion of the sale, the senior vice president now directly owns 2,926 shares of the company’s stock, valued at approximately $125,291.32. This represents a 20.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Christopher Peetz sold 7,489 shares of the firm’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $320,678.98. Following the completion of the transaction, the chief executive officer now directly owns 119,359 shares of the company’s stock, valued at $5,110,952.38. This represents a 5.90 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 19,706 shares of company stock valued at $875,697 in the last three months. 22.87% of the stock is currently owned by corporate insiders.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.